SCHEDULE: Almitas Capital Discloses 5.2% Stake in AN2 Therapeutics
Beneficial Ownership Report
Almitas Capital LLC has reported a 5.2% beneficial ownership stake in AN2 Therapeutics, Inc., holding 1,428,323 shares of common stock and warrants.
Summary
- Almitas Capital LLC reported beneficial ownership of 1,428,323 shares of AN2 Therapeutics, Inc. common stock and warrants.
- This ownership represents 5.2% of the total class of securities.
- Almitas Capital LLC holds sole voting power and sole dispositive power over all 1,428,323 beneficially owned shares.
- The event requiring this filing occurred on September 30, 2025.
- Almitas Capital LLC is classified as an Investment Adviser (IA).
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently drive a strong positive or negative sentiment regarding the issuer's performance or prospects. It simply reports an institutional investor's stake.
Positives
- Almitas Capital LLC, an investment adviser, has taken a significant stake (5.2%) in AN2 Therapeutics, Inc., indicating potential institutional confidence in the company.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- Almitas Capital LLC certifies that, to the best of its knowledge and belief, the information set forth in this statement is true, complete, and correct.
- Almitas Capital LLC undertakes to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.
Industry Context
The disclosure of a significant stake by an investment adviser like Almitas Capital LLC is a routine event in the public markets, signaling institutional investment activity in AN2 Therapeutics, Inc. This type of filing typically reflects a passive investment strategy rather than an intent to influence management or control the company.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence in AN2 Therapeutics, Inc.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires the filing of this statement |
| 11/14/2025 | Date of filing of this statement |
Keywords
AN2 Therapeutics, Almitas Capital, Schedule 13G, beneficial ownership, common stock, warrants, investment adviser, institutional investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.